Literature DB >> 7107028

l-Tyrosine as an immunological adjuvant.

A W Wheeler, D M Moran, B E Robins, A Driscoll.   

Abstract

A series of experiments has been carried out to investigate the adjuvant properties of the amino acid L-tyrosine in laboratory animals. Adsorption of various allergenic materials to L-tyrosine was found to enhance the induction of IgG antibodies, but no unusual propensity to stimulate IgE antibody or delayed hypersensitivity was observed. Administration of the amino acid at a site remote from the allergen was found not to augment antibody production. This, together with evidence of reduced bioavailability of the tyrosine-adsorbed allergen, suggested that the adjuvant activity observed resulted from a short-term depot effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107028     DOI: 10.1159/000233157

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  9 in total

Review 1.  Adjuvants for allergy immunotherapeutics.

Authors:  Carlos Gamazo; Carmen D'Amelio; Gabriel Gastaminza; Marta Ferrer; Juan M Irache
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

2.  Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response.

Authors:  Hiep Khong; Annika Volmari; Meenu Sharma; Zhimin Dai; Chinonye S Imo; Yared Hailemichael; Manisha Singh; Derek T Moore; Zhilan Xiao; Xue-Fei Huang; Thomas D Horvath; David H Hawke; Willem W Overwijk
Journal:  J Immunol       Date:  2018-04-11       Impact factor: 5.422

3.  Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.

Authors:  M D Heath; N J Swan; A C Marriott; N J Silman; B Hallis; C Prevosto; K E Gooch; M A Skinner
Journal:  BMC Infect Dis       Date:  2017-03-27       Impact factor: 3.090

4.  Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling.

Authors:  Deborah S Leuthard; Agathe Duda; Sandra N Freiberger; Sina Weiss; Isabella Dommann; Gabriele Fenini; Emmanuel Contassot; Matthias F Kramer; Murray A Skinner; Thomas M Kündig; Matthew D Heath; Pål Johansen
Journal:  J Immunol       Date:  2018-03-28       Impact factor: 5.422

5.  Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Authors:  Mona O Mohsen; Matthew D Heath; Gustavo Cabral-Miranda; Cyrill Lipp; Andris Zeltins; Marcos Sande; Jens V Stein; Carsten Riether; Elisa Roesti; Lisha Zha; Paul Engeroff; Aadil El-Turabi; Thomas M Kundig; Monique Vogel; Murray A Skinner; Daniel E Speiser; Alexander Knuth; Matthias F Kramer; Martin F Bachmann
Journal:  J Immunother Cancer       Date:  2019-04-26       Impact factor: 13.751

6.  Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.

Authors:  S Zielen; P Kuna; W Aberer; S Lassmann; O Pfaar; L Klimek; A Wade; K Kluehr; J Raab; D Wessiepe; D Lee; M F Kramer; K Gunawardena; T Higenbottam; M D Heath; M A Skinner; P J de Kam
Journal:  World Allergy Organ J       Date:  2019-10-25       Impact factor: 4.084

Review 7.  Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®).

Authors:  Matthew D Heath; Mona O Mohsen; Pieter-Jan de Kam; Thalia L Carreno Velazquez; Simon J Hewings; Matthias F Kramer; Thomas M Kündig; Martin F Bachmann; Murray A Skinner
Journal:  Front Immunol       Date:  2020-11-24       Impact factor: 7.561

8.  The size of micro-crystalline tyrosine (MCT®) influences its recognition and uptake by THP-1 macrophages in vitro.

Authors:  Emma Shardlow; Christopher Exley
Journal:  RSC Adv       Date:  2019-08-07       Impact factor: 4.036

Review 9.  Allergen Immunotherapy: Current and Future Trends.

Authors:  Gandhi F Pavón-Romero; Maria Itzel Parra-Vargas; Fernando Ramírez-Jiménez; Esmeralda Melgoza-Ruiz; Nancy H Serrano-Pérez; Luis M Teran
Journal:  Cells       Date:  2022-01-08       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.